How is TRT dosing approached?
Testosterone replacement therapy is prescribed for men with documented hypogonadism — clinically low testosterone confirmed on at least two morning fasting blood draws, paired with signs or symptoms such as low libido, fatigue, loss of muscle mass, depression, or erectile dysfunction.
The Endocrine Society’s 2018 clinical practice guideline, the primary reference for US clinicians, recommends a target-range approach rather than a fixed dose. The prescribing goal is to restore testosterone to the mid-normal physiological range, typically defined as approximately 400–700 ng/dL total testosterone, with dosing individualized to achieve that range.
No single dose will be right for every patient because testosterone pharmacokinetics vary with body composition, injection volume, ester formulation, and individual metabolism. Labs at 6–12 weeks post-initiation guide dose adjustments.
What are the typical dose ranges for injectable testosterone?
Injectable testosterone esters — testosterone cypionate and testosterone enanthate — are the most widely used TRT formulations in the USA. Both are FDA-approved medications, not compounded preparations. They are dispensed as an oil-based solution administered via intramuscular (IM) or subcutaneous (SQ) injection.
Typical dose range: injectable testosterone
FDA-approved labeling for testosterone cypionate injection cites 50–400 mg every 2–4 weeks for hypogonadism. In clinical practice, however, the every-2-to-4-week protocol is now considered suboptimal for most patients due to the wide peak-trough swing it produces: a surge of testosterone in the days after injection followed by a significant trough before the next dose, which can cause symptomatic variability.
Contemporary clinical practice increasingly uses:
- Weekly injection: 50–150 mg per week (testosterone cypionate or enanthate). This is the most common current clinical protocol and maintains more stable serum levels.
- Twice-weekly injection: 25–75 mg per injection, 50–150 mg per week total. Further smooths the serum curve; commonly used with subcutaneous delivery.
Subcutaneous injection (into the fat layer rather than muscle) is now widely used for convenience and because it produces a slightly slower, more stable absorption curve than IM injection.
The right TRT dose is the one that lands your labs in the mid-normal range and resolves symptoms — not a fixed milligram number copied from someone else.
TRT dose ranges by formulation
| Formulation | Typical dose range | Frequency | Route |
|---|---|---|---|
| Testosterone cypionate | 50–150 mg | Weekly or twice-weekly | IM or SQ injection |
| Testosterone enanthate | 50–150 mg | Weekly or twice-weekly | IM or SQ injection |
| Testosterone gel (e.g., AndroGel 1.62%) | 20.25–40.5 mg | Daily | Topical (skin) |
| Compounded testosterone cream | Clinician-determined | Daily | Topical (skin) |
| Testosterone pellets | Pellet count based on weight & labs | Every 3–6 months | Subcutaneous implant |
| Natesto nasal gel | 5.5 mg per nostril | Three times daily | Intranasal |
Doses reflect typical clinical practice ranges; individual doses are determined by a licensed clinician based on labs and symptom response.
Other TRT formulations and their typical dosing
Topical gels and creams
Testosterone gels (e.g., AndroGel 1.62%) are applied daily to shoulders, upper arms, or inner thighs. Typical starting doses are 20.25–40.5 mg of testosterone per day. Absorption varies significantly between individuals, and transfer to partners or children via skin contact is a documented concern that requires careful application hygiene.
Pellet implants
Testosterone pellets are implanted subcutaneously by a clinician and release testosterone over 3–6 months. Dosing (number of pellets) is calculated based on weight and baseline testosterone level. Pellets are convenient for adherence but dose adjustment requires a new implant procedure — there is no easy titration if the dose is too high.
Nasal gel
Natesto (testosterone nasal gel) is a three-times-daily formulation that has the unique property of minimally suppressing LH and FSH, making it an option for men who wish to preserve fertility while treating hypogonadism symptoms. Typical dosing is 5.5 mg per nostril, three times daily.
Labs required before and during TRT
TRT is labs-first medicine. No responsible clinician prescribes testosterone without baseline laboratory evaluation, and monitoring labs drive every dose adjustment. Standard pre-TRT labs include:
- Total testosterone: Two morning fasting draws (7–10 AM) on separate days to confirm hypogonadism. Testosterone has circadian variation; afternoon draws can understate levels.
- Free testosterone and SHBG: Free testosterone is the biologically active fraction. SHBG (sex hormone-binding globulin) determines how much is free. Men with high SHBG may have normal total T but low free T.
- LH and FSH: These pituitary hormones determine whether hypogonadism is primary (testicular) or secondary (pituitary/hypothalamic). Secondary hypogonadism may have a correctable cause.
- Hematocrit / CBC: Testosterone stimulates red blood cell production. Elevated hematocrit (erythrocytosis) is the most common TRT side effect requiring dose reduction or phlebotomy. Pre-treatment baseline and regular monitoring are essential.
- PSA: Prostate-specific antigen baseline before initiating TRT, particularly in men over 40.
- Estradiol: Testosterone aromatizes to estradiol. Elevated estradiol can cause breast sensitivity, water retention, and mood changes; monitoring guides adjunctive management.
Follow-up labs are drawn at 6–12 weeks after starting or adjusting dose, then every 6–12 months once stable. Hematocrit is the most time-sensitive safety lab during early treatment.
What dose adjustments look like in practice
If 6-week labs show total testosterone below the mid-normal range (e.g., 300 ng/dL on a weekly 80 mg dose), the clinician may increase the dose to 100 mg weekly. If labs show levels above the normal reference range or hematocrit is elevated, the clinician may decrease the dose or extend the interval.
Symptom response also informs adjustment — some men feel substantially better at 500 ng/dL than at 400 ng/dL, and the clinical target is the range where symptoms resolve, not a specific absolute number on the lab report.
Dose stabilization often takes 3–6 months of quarterly adjustments. Once a stable dose is established, annual labs and periodic clinical check-ins maintain ongoing oversight.
What TRT does not do
Testosterone replacement therapy replaces testosterone in men with documented hypogonadism. It does not build muscle in men with normal testosterone levels, is not a performance-enhancing protocol, and is not appropriate use at supraphysiological doses — which carry substantively different risk profiles than physiological replacement. Prescribing TRT at supraphysiological doses is outside the standard of care and creates erythrocytosis and cardiovascular risks that responsible clinicians will not take on.
If you are seeing numbers cited online (300+ mg per week, "blast and cruise" protocols) in the context of TRT, those are not typical TRT doses. Those are anabolic steroid protocols, and they carry a categorically different risk profile.
FAQs: typical TRT dose
What is a typical TRT dose?
A typical TRT dose depends on the formulation. For testosterone cypionate or enanthate injections, clinical guidelines commonly reference 100–200 mg administered every 1–2 weeks, though many clinicians now prefer weekly injections for more stable serum levels. The goal is to restore total testosterone into the normal physiological range (roughly 400–700 ng/dL), and dosing is individualized based on labs and symptom response.
How is TRT dose determined?
Dosing is set by a licensed clinician based on baseline lab results (total testosterone, free testosterone, LH, FSH, hematocrit, PSA), symptom severity, age, and comorbidities. Dose is then adjusted at follow-up lab intervals — typically 6–12 weeks after initiation — to target the patient's therapeutic window without driving supraphysiological levels.
What testosterone levels are the target with TRT?
Most clinical guidelines target mid-normal range for total testosterone: roughly 400–700 ng/dL. Some clinicians target the upper third of normal (500–900 ng/dL) based on symptom response. Supraphysiological levels (above the normal reference range) increase the risk of erythrocytosis, cardiovascular strain, and other side effects.
How often are TRT injections given?
Testosterone cypionate and enanthate are esterified forms that release gradually. Historically, clinical protocols used every-2-week injections, but evidence increasingly supports weekly or even twice-weekly subcutaneous injections for more stable serum testosterone curves, fewer peak-trough symptoms, and lower hematocrit burden.
What lab work is required for TRT?
Before starting TRT, standard labs include: total and free testosterone, LH and FSH (to confirm hypogonadism is not secondary to a pituitary issue), hematocrit/CBC, comprehensive metabolic panel, PSA, and SHBG. Estradiol is also commonly checked. Follow-up labs at 6–12 weeks assess response and screen for erythrocytosis or PSA changes.